Saframycin A
CAS No. 66082-27-7
Saframycin A ( NSC 325663 )
Catalog No. M15514 CAS No. 66082-27-7
A heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
100MG | Get Quote | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSaframycin A
-
NoteResearch use only, not for human use.
-
Brief DescriptionA heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro.
-
DescriptionA heterocyclic quinone antibiotic that inhibits RNA synthesis in vivo and in vitro; shows potent antiproliferative effects in leukemia- and tumor-derived cells; induces nuclear translocation of GAPDH in cancer cells.
-
SynonymsNSC 325663
-
PathwayCell Cycle/DNA Damage
-
TargetDNA/RNA Synthesis
-
RecptorDNA/RNA Synthesis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number66082-27-7
-
Formula Weight562.58
-
Molecular FormulaC29H30N4O8
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOC1=C(C(C2=C(C1=O)[C@@H](N3[C@H]([C@H]4N([C@@H]([C@@H]3C#N)CC5=C4C(C(OC)=C(C5=O)C)=O)C)C2)CNC(C(C)=O)=O)=O)C
-
Chemical NameN-[[(6S,7R,9R,14aS,15R)-7-Cyano-1,5,6,7,9,10,13,14,14a,15-decahydro-2,11-dimethoxy-3,12,16-trimethyl-1,4,10,13-tetraoxo-6,15-imino-4H-isoquino[3,2-b][3]benzazocin-9-yl]methyl]-2-oxopropanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Xing C, et al. Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5862-6.
2. Ishiguro K, et al. Biochemistry. 1978 Jun 27;17(13):2545-50.
3. Spencer JR, et al. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4884-8.
2. Ishiguro K, et al. Biochemistry. 1978 Jun 27;17(13):2545-50.
3. Spencer JR, et al. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4884-8.
molnova catalog
related products
-
Helicid
Helicid is a medicine available in a number of countries worldwide.
-
Beaucage reagent
A potent DNA cleavage agent.
-
CCG-203971
CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50: 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM.